L-arginine and allopurinol protect against cyclosporine nephrotoxicity

被引:41
作者
Assis, SM [1 ]
Monteiro, JL [1 ]
Seguro, AC [1 ]
机构
[1] UNIV SAO PAULO,HOSP CLIN,FAC MED,LAB INVEST MED NEFROL,SAO PAULO,BRAZIL
关键词
D O I
10.1097/00007890-199704270-00004
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The role of nitric oxide (NO) and oxygen free radicals in cyclosporine (CsA) nephrotoxicity was investigated using L-arginine, an NO substrate, and allopurinol, a xanthine oxidase inhibitor (involved in the formation of oxygen radicals) in an experimental model with Wistar rats. CsA, administered at 15 mg/kg/body weight (BW) subcutaneously for 10 days, caused a decrease in glomerular filtration rate, with inulin clearance of 0.33+/-0.04 vs. 1.11+/-0.06 ml/min/100 g BW (P<0.01 vs. control). L-Arginine, 1.5% in drinking water 5 days before and during CsA administration partially protected the animals against this fall in glomerular filtration rate, with inulin clearance of 0.68+/-0.03 ml/min/100 g BW (P<0.01 vs. CsA). Allopurinol, at 10 mg/kg/BW by gavage, also had a protective action, with inulin clearance of 0.54+/-0.04 ml/min/100 g (P<0.01 vs. CsA). CsA caused an elevation in NO production, as assessed by urinary excretion of its metabolites, nitrite and nitrate (NO2 and NO3; 0.836+/-0.358 vs. 0.107+/-0.019 nmol/mu g creatinine). NO production was as much as threefold higher in the L-arginine group (1.853+/-0.206 nmol/g creatinine). This CsA effect is probably related to its vasoconstrictive stimulus. Supplementation with L-arginine, which provides more substrate for NO formation, may enhance vasodilatation and consequently reduce the impairment of renal function. The protection provided by allopurinol may be related to the reduced formation of oxygen radicals, preventing the deleterious effects of lipid peroxidation.
引用
收藏
页码:1070 / 1073
页数:4
相关论文
共 38 条
[1]   A POSSIBLE ROLE FOR NITRIC-OXIDE IN MODULATING THE FUNCTIONAL CYCLOSPORINE TOXICITY BY ARGININE [J].
AMORE, A ;
GIANOGLIO, B ;
GHIGO, D ;
PERUZZI, L ;
PORCELLINI, MG ;
BUSSOLINO, F ;
COSTAMAGNA, C ;
CACACE, G ;
PICCIOTTO, G ;
MAZZUCCO, G ;
SENA, LM ;
COPPO, R .
KIDNEY INTERNATIONAL, 1995, 47 (06) :1507-1514
[2]   ORAL-ADMINISTRATION OF L-ARGININE AND CAPTOPRIL IN RATS PREVENTS CHRONIC-RENAL-FAILURE BY NITRIC-OXIDE PRODUCTION [J].
ASHAB, I ;
PEER, G ;
BLUM, M ;
WOLLMAN, Y ;
CHERNIHOVSKY, T ;
HASSNER, A ;
SCHWARTZ, D ;
CABILI, S ;
SILVERBERG, D ;
IAINA, A .
KIDNEY INTERNATIONAL, 1995, 47 (06) :1515-1521
[3]   GLOMERULAR HEMODYNAMICS AND HORMONAL PARTICIPATION ON CYCLOSPORINE NEPHROTOXICITY [J].
BARROS, EJG ;
BOIM, MA ;
AJZEN, H ;
RAMOS, OL ;
SCHOR, N .
KIDNEY INTERNATIONAL, 1987, 32 (01) :19-25
[4]  
BATTLE DC, 1986, CLIN NEPHROL S1, V25, pS62
[5]  
BENNETT WM, 1994, NEPHROL DIAL TRANSPL, V9, P141
[6]   SIDE-EFFECTS OF CYCLOSPORINE-A TREATMENT IN PATIENTS WITH RHEUMATOID-ARTHRITIS [J].
BERG, KJ ;
FORRE, O ;
BJERKHOEL, F ;
AMUNDSEN, E ;
DJOSELAND, O ;
RUGSTAD, HE ;
WESTRE, B .
KIDNEY INTERNATIONAL, 1986, 29 (06) :1180-1187
[7]   AN EXPERIMENTAL-STUDY OF ALTERED NITRIC-OXIDE METABOLISM AS A MECHANISM OF CYCLOSPORINE-INDUCED RENAL VASOCONSTRICTION [J].
BLOOM, ITM ;
BENTLEY, FR ;
SPAIN, DA ;
GARRISON, RN .
BRITISH JOURNAL OF SURGERY, 1995, 82 (02) :195-198
[8]   EXPERIMENTAL NEPHROTOXICITY, HEPATOTOXICITY AND PHARMACOKINETICS OF CYCLOSPORINE-G VERSUS CYCLOSPORINE-A [J].
BURDMANN, EA ;
ANDOH, TF ;
ROSEN, S ;
LINDSLEY, J ;
MUNAR, MY ;
ELZINGA, LW ;
BENNETT, WM .
KIDNEY INTERNATIONAL, 1994, 45 (03) :684-691
[9]   LOW-DOSE ALLOPURINOL PLUS AZATHIOPRINE CYCLOSPORINE PREDNISOLONE, A NOVEL IMMUNOSUPPRESSIVE REGIMEN [J].
CHOCAIR, P ;
DULEY, J ;
SIMMONDS, HA ;
CAMERON, JS ;
IANHEZ, L ;
ARAP, S ;
SABBAGA, E .
LANCET, 1993, 342 (8863) :83-84
[10]   THE IMPORTANCE OF THIOPURINE METHYLTRANSFERASE ACTIVITY FOR THE USE OF AZATHIOPRINE IN TRANSPLANT RECIPIENTS [J].
CHOCAIR, PR ;
DULEY, JA ;
SIMMONDS, HA ;
CAMERON, JS .
TRANSPLANTATION, 1992, 53 (05) :1051-1056